
Cervical cancer is the fourth most common cancer in women globally, and the seventh overall, with an estimated 528,000 new cases in 2012 [1]. There were an estimated 266,000 deaths from cervical cancer worldwide in 2012, accounting for 7.5% of all female cancer deaths [1]. Almost nine out of ten (87%) cervical cancer deaths occur in the less developed regions1. Cervical cancer is a near preventable disease. Together, cervical cancer screening and the HPV vaccine could prevent as many as 93% of all cervical cancers [2]. Timely screening leads to detection of early warning signs and provides an opportunity for institution of correct management in the precancerous stage. The frequency of screening and the choice of the test used have been under debate by health care providers, physicians, researchers and women themselves. The aim today is to maintain a balance between benefits of early detection and perils of over-testing.
Pap smear was introduced in the late 1920s as a screening test for cervical cancer and has been widely used since then. Time wears things down – but this does not seem to hold true for Pap smear. Despite of high false negative rates, cervical cancer incidence decreased with time. 1976 witnessed the publication of the Nobel award winning hypothesis “HPV is involved in causing cervical cancer.” By the end of the 20th century, carcinogenicity was linked to high risk HPV types 16 and 18. Cervical cancer screening was recommended every three years at that time. Very soon, liquid based cytology emerged as a new and more efficient tool for screening. The role of persistent carcinogenic HPV infections virtually underlying all cases of cervical cancer became well established. Testing for HPV thus became an attractive proposition for detecting cervical cancer. Quadrivalent HPV vaccine was introduced in 2006 along with a new test to detect HPV – the HPV DNA test. Trends drifted from only a conventional Pap smear to liquid based cervical cytology and finally co-testing.
U.S. Preventive Services Task Force Recommendation (USPSTF), American Cancer society (ACS), American College of Obstetricians and Gynecologists (ACOG) and American Society for Colposcopy and Cervical Pathology (ASCCP) after a consensus conference agreed on recommendations for routine cervical cancer screening [3]. Routine screening was recommended to commence at age 21, despite of HPV vaccine administration. Women aged 21-29 years were advised Pap test screening every 3 years. Women aged 30-65 years had the option of either having a Pap test every 3 years, or having a Pap test plus an HPV test (co-testing) every 5 years. More frequent screening did not provide more protection. Routine screening was not recommended after the age of 65 years, given a history of normal screenings. Women with a history of CIN2 or a more severe diagnosis were advised to continue routine screening for at least 20 years. Screening was not recommended after a total hysterectomy and in the absence of a history of high-grade precancerous lesions. These recommendations were for routine screening and some women may need an individualized screening schedule because of their health history or previous screening results.
In 2015, guidelines4 were issued stating that “primary hrHPV (high risk HPV) screening can be considered as an alternative to current US cytology-based cervical cancer screening methods. Cytology alone and co-testing remain the screening options. Primary hrHPV screening should not be initiated prior to 25 years age. Re-screening after a negative primary hrHPV screen should occur no sooner than every 3 years”. At present, there are four FDA approved hrHPV assays that are commercially available, but only one of these assays is now FDA-approved specifically for primary screening. The American College of Physicians (ACP) issued its best-practice advice5 for cervical cancer screening in April 2015. ACP specifically recommends against testing more often than every three years in average-risk women age 21 to 65. It says clinicians may use co-testing - Pap plus HPV test - once every five years for women over 30.
- http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
- Benard VB., et al. “Vital signs: cervical cancer incidence, mortality, and screening-United States, 2007-2012”. MMWR. Morbidity and mortality weekly report 6.44 (2014): 1004-1009.
- L Stewart Massad., et al. “2012 ASCCP Consensus Guidelines Conference 2013, American Society for Colposcopy and Cervical Pathology”. Journal of Lower Genital Tract Disease 17.5 (2013): S1-S27.
- Huh WK., et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance”. Gynecologic Oncology 125.2 (2015): 330-337.
- Sawaya GF., et al. “Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians”. Annals Internal Medicine 162.12 (2015): 851-859.
Journal Menu
PubMed Indexed Article
EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.
PMID: 31143884 [PubMed]
PMCID: PMC6536005
EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.
PMID: 31565701 [PubMed]
PMCID: PMC6764777
EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.
PMID: 27747317 [PubMed]
PMCID: PMC5065347
EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?
PMID: 31460519 [PubMed]
PMCID: PMC6711478
EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?
PMID: 30215059 [PubMed]
PMCID: PMC6133253
EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.
PMID: 30417173 [PubMed]
PMCID: PMC6226033
EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.
PMID: 30264037 [PubMed]
PMCID: PMC6155992
EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.
PMID: 30198026 [PubMed]
PMCID: PMC6124505
EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.
PMID: 30294723 [PubMed]
PMCID: PMC6169793
EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs
PMID: 29285526 [PubMed]
PMCID: PMC5743211
EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique
PMID: 29911204 [PubMed]
PMCID: PMC5999047
EC Microbiology
Macrophages and the Viral Dissemination Super Highway
PMID: 26949751 [PubMed]
PMCID: PMC4774560
EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.
PMID: 27390782 [PubMed]
PMCID: PMC4933318
EC Microbiology
Reactive Oxygen Species in HIV Infection
PMID: 28580453 [PubMed]
PMCID: PMC5450819
EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population
PMID: 26280024 [PubMed]
PMCID: PMC4533840
EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis
PMID: 28066845 [PubMed]
PMCID: PMC5214344
EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology
PMID: 28936490 [PubMed]
PMCID: PMC5604476
EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia
PMID: 28713879 [PubMed]
PMCID: PMC5510658
EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature
PMID: 28133641 [PubMed]
PMCID: PMC5267489
EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling
PMID: 29333536 [PubMed]
PMCID: PMC5766278
EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.
PMID: 31032493 [PubMed]
PMCID: PMC6483108
EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.
PMID: 30957099 [PubMed]
PMCID: PMC6448571
EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.
PMID: 30101228 [PubMed]
PMCID: PMC6086333
EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.
PMID: 31080964 [PubMed]
PMCID: PMC6508883
EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.
PMID: 31093608 [PubMed]
PMCID: PMC6513001
EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.
PMID: 31552397 [PubMed]
PMCID: PMC6758937
EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.
PMID: 31681909 [PubMed]
PMCID: PMC6824723
EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.
PMID: 31681910 [PubMed]
PMCID: PMC6824726
EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.
PMID: 31528859 [PubMed]
PMCID: PMC6746603
EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?
PMID: 31276119 [PubMed]
PMCID: PMC6604646
EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.
PMID: 31406965 [PubMed]
PMCID: PMC6690616
EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.
PMID: 31517314 [PubMed]
PMCID: PMC6741290
EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.
PMID: 31633124 [PubMed]
PMCID: PMC6800226
EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.
PMID: 29662969 [PubMed]
PMCID: PMC5898812
EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.
PMID: 30215058 [PubMed]
PMCID: PMC6133268
News and Events
August Issue Release
We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the August issue of respective journals and the latest articles can be viewed on the current issue pages.
Submission Deadline for Upcoming Issue
ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before August 18, 2022.
Certificate of Publication
ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.
Best Article of the Issue
Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.
Certifying for Review
ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.
Latest Articles
The latest articles will be updated immediately on the articles in press page of the respective journals.